BPC-157 vs TB-500: Healing Peptides Compared (and Why People Stack Them)

BPC-157 and TB-500 are the two most-discussed research peptides for tissue repair — and the most common question is which to use, or whether to use both. This guide compares their origins, mechanisms, what each repairs best, dosing rhythm, and safety, then explains why they are so often combined. For the single-compound deep dives, see What Is BPC-157? and What Is TB-500?.

The Short Answer

BPC-157 is a short, fast-acting, locally-oriented healer with a gut/tendon specialty; TB-500 is a longer-acting, systemic regenerator that drives cell migration and new blood-vessel growth body-wide. They work through different, complementary pathways — which is why the "BPC-157 + TB-500" combination (the Wolverine Stack) is one of the most popular research protocols. Neither is FDA-approved, both are prohibited in competitive sport by WADA, and most evidence is preclinical. (BPC-157 systematic review, Thymosin β4 review)

Origin & Structure

• BPC-157 (Body Protection Compound‑157) is a synthetic 15-amino-acid fragment (Gly‑Glu‑Pro‑Pro‑Pro‑Gly‑Lys‑Pro‑Ala‑Asp‑Asp‑Ala‑Gly‑Leu‑Val) derived from a protective protein in human gastric juice. MW ≈1,419 Da. (BPC-157 systematic review)
• TB-500 is a synthetic 7-amino-acid fragment (Ac‑LKKTETQ) of thymosin beta‑4 (Tβ4), a naturally occurring 43-amino-acid actin-binding protein found in nearly all human cells. Most formal clinical work has used the full Tβ4 protein. (Thymosin β4 review)

Side-by-Side Snapshot

How They Heal: Different Tools

BPC-157 — the local, anti-inflammatory repairer. It promotes new blood-vessel growth via VEGF, up-regulates growth-factor and growth-hormone-receptor signaling in tendon cells, boosts nitric-oxide activity, and sharply dampens inflammation (IL-6, TNF-α, COX-2, myeloperoxidase). Its origin in the stomach gives it a distinctive gut-protective profile — healing ulcers and protecting against NSAID-induced gut injury — alongside tendon and ligament repair. Its short half-life means it is typically dosed daily, and many users inject near the injury site. (BPC-157 systematic review)

TB-500 — the systemic mobilizer. By binding G-actin and regulating the cytoskeleton, it accelerates the migration of endothelial cells, fibroblasts, keratinocytes, and stem cells into wound sites. It drives angiogenesis (recruiting endothelial progenitor cells, up-regulating VEGF), reduces fibrosis for more organized repair tissue, and is anti-apoptotic in cardiac and neural models. Its big differentiator is systemic distribution — after a subcutaneous injection it reaches distant tissues, so injection site is flexible. Early work showed Tβ4 accelerated wound closure by ~42–61%. (Thymosin β4 review, Wound healing, Angiogenesis)

Why People Stack Them: The Wolverine Stack

The two peptides don't overlap — they cover different facets of healing, which is exactly why they're combined:

• BPC-157 brings localized repair, gut protection, and strong anti-inflammatory action.
• TB-500 brings systemic reach, cell migration, and anti-fibrotic remodeling.

Together they're known as the Wolverine Stack, one of the most popular research combinations for soft-tissue recovery. There's no known mutual interference, and anecdotal reports describe additive improvements in tendon and muscle recovery. See the Wolverine Stack guide and the Wolverine Stack Dosage Protocol. For a copper-tripeptide variant that adds matrix remodeling, the GLOW blend pairs these with GHK-Cu.

Dosing & Handling

• BPC-157: once-daily subcutaneous injection, commonly 200–600 µg, in cycles of ~8–12 weeks. See the BPC-157 5 mg / 10 mg protocols and the BPC-157 calculator.
• TB-500: a two-phase rhythm — 2.5 mg twice weekly for ~4–6 weeks (loading), then 2.5 mg once weekly or every two weeks (maintenance). See the TB-500 5 mg Protocol and the TB-500 calculator.

Both are reconstituted with bacteriostatic water, stored at 2–8 °C after mixing, and handled with sterile technique. For the shared mechanics, see How to Reconstitute Peptides.

Safety & Status

Neither peptide is FDA-approved; both are research compounds. In animal studies BPC-157 has shown a remarkably clean toxicity profile (no organ damage even at very high doses, non-mutagenic), though long-term human data are absent and its angiogenic action prompts theoretical caution in anyone with active cancer. TB-500/Tβ4 has been studied in human wound-healing and cardiac contexts and was generally well tolerated in early trials. Both are on the WADA Prohibited List and should not be used by athletes subject to anti-doping rules. (BPC-157 systematic review, Thymosin β4 review)

FAQ

What is the difference between BPC-157 and TB-500?
BPC-157 is a 15-amino-acid gastric peptide that works locally, is strongly anti-inflammatory, and specializes in tendon, ligament, and gut healing. TB-500 is a 7-amino-acid fragment of thymosin beta-4 that distributes systemically, drives cell migration and angiogenesis, and reduces fibrosis. They use different mechanisms, which is why they complement rather than duplicate each other. (BPC-157 review, Thymosin β4 review)

Can you take BPC-157 and TB-500 together?
Yes — combining them is the most popular research protocol, known as the Wolverine Stack. BPC-157 provides localized, anti-inflammatory healing while TB-500 provides systemic repair and angiogenesis. There is no known mutual interference, and the mechanisms complement each other. See the Wolverine Stack guide.

Which is better for tendon injuries?
For tendon and ligament injuries, many find BPC-157 particularly effective because it reduces local inflammation and pain while promoting repair, and it can be injected near the injury. TB-500 contributes systemic repair and is often added for larger or multi-site injuries. The two are frequently used together for stubborn tendon problems.

How are the dosing schedules different?
BPC-157 has a short (~30 minute) half-life, so it's typically injected once daily at 200–600 µg. TB-500 lasts much longer, so it's dosed less often but in larger amounts — commonly 2.5 mg twice weekly during a loading phase, then once weekly or biweekly for maintenance.

Are BPC-157 and TB-500 legal or approved?
Neither is approved by the FDA for human therapeutic use; both are sold as research compounds. Both are also on the World Anti-Doping Agency Prohibited List, so athletes subject to anti-doping rules should avoid them. Most supporting evidence is preclinical, so any use is essentially experimental.

Do BPC-157 or TB-500 have serious side effects?
In animal studies BPC-157 has shown a very clean safety profile with no organ toxicity even at high doses, though long-term human data are lacking and its blood-vessel-promoting action raises theoretical caution in people with active cancer. TB-500/thymosin beta-4 was generally well tolerated in early human wound-healing trials. Mild injection-site reactions and fatigue are reported anecdotally for both.

Next Steps

For step-by-step reconstitution math, see the BPC-157 and TB-500 protocols, or use the peptide dosage calculator. To run both together, read the Wolverine Stack guide.

Bottom line: BPC-157 is the local, anti-inflammatory specialist; TB-500 is the systemic regenerator. For comprehensive soft-tissue recovery, they're more often combined than chosen between.